Winship Cancer Institute of Emory University at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Winship Cancer Institute of Emory University brings 1 presentation to ASH 2026 in New Orleans. Its program centres on multiple myeloma, from bringing bispecific antibodies into community practice to choosing the next therapy after relapse. It also looks at how lipids help myeloma cells resist treatment.
| Organization | ASH 2026 Attendance |
|---|---|
Winship Cancer Institute of Emory University Atlanta, GA | |
Emory University's NCI-designated comprehensive cancer center in Atlanta, Georgia. | Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Symposium Fri Dec 11 7:00pm–10:00pm Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis Recognizing the full symptom burden of non-advanced systemic mastocytosis, judging disease control, and deciding when to escalate to disease-directed therapy. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Talk Lipids and Therapy Resistance in Multiple Myeloma How fatty acids shift myeloma cells' reliance on a cell-survival protein and change their sensitivity to the drug venetoclax. |
Instantly find 20 buyers from Winship Cancer Institute of Emory University
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction